Joel Rothman - Equillium Chief Officer
| EQ Stock | USD 0.63 0.03 4.55% |
Insider
Joel Rothman is Chief Officer of Equillium
| Age | 55 |
| Address | 2223 Avenida De La Playa, La Jolla, CA, United States, 92037 |
| Phone | 858 240 1200 |
| Web | https://www.equilliumbio.com |
Joel Rothman Latest Insider Activity
Tracking and analyzing the buying and selling activities of Joel Rothman against Equillium stock is an integral part of due diligence when investing in Equillium. Joel Rothman insider activity provides valuable insight into whether Equillium is net buyers or sellers over its current business cycle. Note, Equillium insiders must abide by specific rules, including filing SEC forms every time they buy or sell Equillium'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Joel Rothman over three months ago Acquisition by Joel Rothman of 7742 shares of Equillium at 2.35 subject to Rule 16b-3 | ||
Joel Rothman over six months ago Acquisition by Joel Rothman of 8804 shares of Equillium subject to Rule 16b-3 |
Equillium Management Efficiency
The company has Return on Asset (ROA) of (0.1195) % which means that for every 100 dollars spent on asset, it generated a loss of $0.1195. This is way below average. Likewise, it shows a return on total equity (ROE) of (0.3367) %, which implies that it produced no returns to current stockholders. Equillium's management efficiency ratios could be used to measure how well Equillium manages its routine affairs as well as how well it operates its assets and liabilities. As of 12/19/2024, Return On Tangible Assets is likely to drop to -0.28. In addition to that, Return On Capital Employed is likely to drop to -0.66. At this time, Equillium's Total Current Liabilities is relatively stable compared to the past year. As of 12/19/2024, Liabilities And Stockholders Equity is likely to grow to about 67.5 M, while Non Current Liabilities Total is likely to drop slightly above 364.8 K.Similar Executives
| Showing other executives | INSIDER Age | ||
| Scott Smith | Bioatla | 62 | |
| Edith MD | Bolt Biotherapeutics | 67 | |
| Andrew MBA | Monopar Therapeutics | 52 | |
| Christine MBA | Hookipa Pharma | 59 | |
| Chulani Karunatilake | Werewolf Therapeutics | 64 | |
| Susannah Walpole | Spero Therapeutics | N/A | |
| Edgar MD | Bolt Biotherapeutics | 78 | |
| Rebecca Sunshine | Coherus BioSciences | 61 | |
| MBA CFA | Bolt Biotherapeutics | 60 | |
| Bruce MD | Bolt Biotherapeutics | N/A | |
| Jeffrey Ecsedy | Ikena Oncology | 54 | |
| Philippe Martin | Bioatla | 48 | |
| James Brady | Spero Therapeutics | N/A | |
| MBA CMA | SAB Biotherapeutics | 69 | |
| Klaus Orlinger | Hookipa Pharma | 46 | |
| Joseph Zakrzewski | AN2 Therapeutics | 62 | |
| Dr Roberts | Lyra Therapeutics | 56 | |
| AFPM MD | Trevi Therapeutics | 57 | |
| MBA MD | Spero Therapeutics | 43 | |
| Ming Yin | Bolt Biotherapeutics | N/A | |
| Cynthia SeidelDugan | Werewolf Therapeutics | 65 | |
Management Performance
| Return On Equity | -0.34 | ||||
| Return On Asset | -0.12 |
Equillium Leadership Team
Elected by the shareholders, the Equillium's board of directors comprises two types of representatives: Equillium inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Equillium. The board's role is to monitor Equillium's management team and ensure that shareholders' interests are well served. Equillium's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Equillium's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jason Keyes, Chief Officer | ||
| PMP MBA, Senior COO | ||
| Matthew Ritter, Senior Development | ||
| Penny Tom, Principal Officer | ||
| Maple MD, Chief Officer | ||
| Krishna MD, Consultant | ||
| Daniel Bradbury, Chairman of the Board, CEO | ||
| Bruce CFA, President, CoFounder | ||
| Joel Rothman, Chief Officer | ||
| Michael Moore, Vice Communications | ||
| Stephen Connelly, Chief Scientific Officer, Director |
Equillium Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Equillium a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.34 | ||||
| Return On Asset | -0.12 | ||||
| Profit Margin | (0.20) % | ||||
| Operating Margin | (0.01) % | ||||
| Current Valuation | (2 M) | ||||
| Shares Outstanding | 35.43 M | ||||
| Shares Owned By Insiders | 36.20 % | ||||
| Shares Owned By Institutions | 20.03 % | ||||
| Number Of Shares Shorted | 131.7 K | ||||
| Price To Earning | (6.70) X |
Pair Trading with Equillium
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Equillium position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Equillium will appreciate offsetting losses from the drop in the long position's value.Moving together with Equillium Stock
Moving against Equillium Stock
| 0.49 | DYAI | Dyadic International | PairCorr |
| 0.48 | BMY | Bristol Myers Squibb | PairCorr |
| 0.35 | GILD | Gilead Sciences | PairCorr |
| 0.34 | ESPR | Esperion Therapeutics | PairCorr |
The ability to find closely correlated positions to Equillium could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Equillium when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Equillium - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Equillium to buy it.
The correlation of Equillium is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Equillium moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Equillium moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Equillium can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Equillium Stock Analysis
When running Equillium's price analysis, check to measure Equillium's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Equillium is operating at the current time. Most of Equillium's value examination focuses on studying past and present price action to predict the probability of Equillium's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Equillium's price. Additionally, you may evaluate how the addition of Equillium to your portfolios can decrease your overall portfolio volatility.